The European Council guidelines clearly provide such transition
arrangements, which should be in the interest of the EU. But according
to the European Commission, it is still “too early” for this discussion.
A UK spokesperson told EURACTIV.com, “We have been clear about our
desire to retain a close working partnership on medicines regulation
after the UK leaves the EU.”
“As we move to our future partnership, we are proposing a
time-limited implementation period where we continue to have access to
one another’s markets on current terms,” the UK official emphasised.
Previously, the associations representing the European and British
life science industry, such as the European Federation of Pharmaceutical
Industries and Associations (EFPIA), Association of the British
Pharmaceutical Industry (ABPI), EuropaBio and Medicines for Europe,
issued a joint statement noting it was important to secure cooperation
between the UK and EU on medicines regulation.
(...)
Sem comentários:
Enviar um comentário